Suppr超能文献

在进行减低强度或清髓性预处理后进行T细胞去除的异基因干细胞移植后,巨细胞病毒感染的发生率和严重程度相当。

Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning.

作者信息

Kalpoe J S, van der Heiden P L J, Vaessen N, Claas E C J, Barge R M, Kroes A C M

机构信息

Department of Medical Microbiology, Leiden University Medical Center, Albinudreef 2, 2300 RC Leiden, The Netherlands.

出版信息

Bone Marrow Transplant. 2007 Jul;40(2):137-43. doi: 10.1038/sj.bmt.1705701. Epub 2007 May 28.

Abstract

Reports on infectious complications following reduced intensity conditioning (RIC) before allogeneic stem cell transplantation (allo-SCT) are equivocal. This prospective follow-up study compared the impact of cytomegalovirus (CMV) infections following RIC with fludarabine, ATG and busulphan or conventional myeloablative conditioning (MAC). Forty-eight RIC and 59 MAC patients were enrolled. The occurrence and severity of CMV infections within 100 days following allo-SCT were assessed, using plasma CMV DNA load kinetics. CMV DNAemia was observed in 21 RIC (60%) and in 19 MAC (44%) patients at risk for CMV. The mean CMV DNAemia free survival time was comparable following RIC and MAC: 70 days (95% (confidence interval) CI: 59-80 days) and 77 days (95% CI: 68-86 days), respectively (P=0.24). Parameters indicative for the level of CMV reactivation, including the area under the curve of CMV DNA load over time as well as the onset, the peak values and duration of CMV infection episodes, the numbers and duration of CMV treatment episodes and recurrent infections, were not different in both groups. During follow-up, none of the patients developed CMV disease. RIC with fludarabine, ATG and busulphan demonstrated safety comparable to conventional MAC with regard to frequency and severity of CMV infections within 100 days following T cell-depleted allo-SCT.

摘要

关于异基因干细胞移植(allo - SCT)前减低剂量预处理(RIC)后感染性并发症的报道并不明确。这项前瞻性随访研究比较了氟达拉滨、抗胸腺细胞球蛋白(ATG)和白消安进行RIC预处理与传统清髓性预处理(MAC)后巨细胞病毒(CMV)感染的影响。纳入了48例接受RIC预处理和59例接受MAC预处理的患者。采用血浆CMV DNA载量动力学评估allo - SCT后100天内CMV感染的发生情况和严重程度。在有CMV感染风险的患者中,21例(60%)接受RIC预处理的患者和19例(44%)接受MAC预处理的患者出现了CMV血症。接受RIC预处理和MAC预处理后,CMV血症-free生存时间相当:分别为70天(95%置信区间(CI):59 - 80天)和77天(95%CI:68 - 86天)(P = 0.24)。两组中指示CMV再激活水平的参数,包括CMV DNA载量随时间变化曲线下的面积以及CMV感染发作的起始、峰值和持续时间、CMV治疗发作的次数和持续时间以及复发性感染,均无差异。在随访期间,没有患者发生CMV疾病。在T细胞去除的allo - SCT后100天内,就CMV感染的频率和严重程度而言,氟达拉滨、ATG和白消安进行的RIC预处理显示出与传统MAC预处理相当的安全性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验